ReproCell Stock

ReproCell Days Payable Outstanding

The Days Payable Outstanding (DPO) of ReproCell (4978.T) as of Sep 5, 2026 is 35.99. In the previous year, Days Payable Outstanding (DPO) was 47.55 — a change of -24.30% (lower).

Days Payable Outstanding

35.99

YoY

-24.30%

Last updated:

Days Payable Outstanding (DPO) of ReproCell is 2026 35.99 . Days Payable Outstanding (DPO) of ReproCell was 2025 47.55 . It decreases by -24.30% lower compared to the previous year.

The ReproCell Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
47.54 JPY
Jan 1, 2019
57.34 JPY
Jan 1, 2020
37.87 JPY
Jan 1, 2021
66.30 JPY
Jan 1, 2022
74.79 JPY
Jan 1, 2023
41.70 JPY
Jan 1, 2024
47.55 JPY
Jan 1, 2025
35.99 JPY
The ReproCell Days Payable Outstanding history
YEARDays Payable OutstandingYoY
35.99-24.30%
47.55+14.03%
41.70-44.24%
74.79+12.80%
66.30+75.06%
37.87-33.96%
57.34+20.63%
47.54+5.96%
44.86-37.72%
72.04-6.62%
77.15-11.30%
86.97
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Days Payable Outstanding (DPO) of ReproCell is 35.99 in 2026.

Days Payable Outstanding (DPO) of ReproCell changed from 47.55 to 35.99, representing a -24.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) ReproCell since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s ReproCell with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

Profitability — ReproCell

All Key Metrics — ReproCell